{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.25","value":"4.06"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"title":"Mean Change in FSFI At the 3-Month Follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.41","value":"4.53"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"title":"Mean Change in FSFI At the 6-Month Follow-up"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Female Sexual Function Index (FSFI) is a validated, self-reported 19-item questionnaire that assesses domains of sexual function, including desire, arousal, lubrication, orgasm, satisfaction, and pain. The aggregated FSFI score is a sum of weighted answers for each of the 19 items in the questionnaire, with a maximum total score possible of 36.0 (high level of sexual functional) and minimum score of 2.0 (low level of sexual functional). Change = (Follow-up score - Baseline score). Mean change was calculated for all scores at the 3- and 6-month follow-ups.","dispersionType":"Standard Error","groups":[{"description":"All eligible subjects that underwent up to 5 treatments at 4±1-week intervals to the vulva with a fractional CO2 laser and maintained the protocol regimen.\n\nThe CO2RE® System: The CO2RE® system is a fractional CO2 laser that is FDA-cleared under a 510(k) K181523 for laser incision, excision, ablation and/or vaporization and of soft tissue in gynecology (GYN).","id":"OG000","title":"CO2RE® Treatment"}],"paramType":"MEAN","populationDescription":"At Baseline, 12 patients completed FSFI questionnaires. At the 3-month visit, 11 subjects completed the FSFI (one subject missed the visit). At the 6-month follow-up, 12 subjects completed the FSFI (one subject missed her visit but provided her self-assessments remotely).","reportingStatus":"POSTED","timeFrame":"Baseline and 3 months and 6 months after the final treatment","title":"Change From Baseline in Sexual Function on the Female Sexual Function Index (FSFI) at 3 Months and 6 Months After the Final Treatment","type":"SECONDARY","unitOfMeasure":"units on a scale"}